Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

Press release content from Business Wire. The AP news staff was not involved in its creation.

Related Keywords

Germany ,Ingelheim ,Rheinland Pfalz ,United States ,Stephan Thalen ,Richard Haynes ,Colin Baigent ,Waheed Jamal ,Sarah Reimer ,Anne Whitehouse ,Eli Lilly ,Martin Landray ,William Herrington ,Jeff Emmick ,University Of Oxford ,Steering Committee ,Oxford Population Health ,Boehringer Ingelheim ,Data Monitoring Committee ,Population Health Research Unit ,Product Development ,Clinician Scientist Oxford Population Health ,Research Council ,Independent Data Monitoring ,Medical Research Council ,Health Research Unit ,Associate Professor William Herrington ,Honorary Consultant Nephrologist ,Professor Richard Haynes ,Corporate Vice President ,Cardiometabolic Medicine ,Vice President ,Professor Colin ,Randomised Evaluation ,Professor Sir Martin ,Public Engagement ,Oxford Population ,Business Wire ,Health ,Business ,Medical Research ,England ,Oxford ,Kidney Disease ,Europe ,Eli Lilly And Co ,